Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Attovia Therapeutics, Inc.

NASDAQ: ATTO · Life Sciences · 2 alerts · CIK 2058707

Share price
$14.73Close, Nov 16
Market cap
$672M
Shares outstanding
45.65MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Attovia Therapeutics, Inc. filings on SEC EDGAR ↗

4:11 PM ET 8-K
Clinical Trial Data

Attovia Therapeutics Clinical Trial Data

Attovia Therapeutics announced positive topline 12-week results from its Phase 1b study of ATTO-1310 in patients with chronic pruritus and high-itch atopic dermatitis. The data showed rapid and sustained itch relief with 82% of chronic pruritus patients achieving a clinically meaningful reduction in itch at Week 12, supporting the potential for quarterly maintenance dosing.

“The recently announced 12-week topline results from our ATTO-1310 Phase 1b trial exceeded our expectations, building on the compelling Week 4 findings and providing further evidence supporting our differentiated target product profile: rapid, deep, and durable itch relief, meaningful skin lesion improvements, the potential for quarterly dosing, and a favorable safety profile.”

Tao Fu, Founder and Chief Executive Officer of Attovia

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.